Holen Sie sich die Stockscreener-App
63.76
0.38%
0.20
Schlusskurs vom Vortag:
$63.56
Offen:
$64.31
24-Stunden-Volumen:
733.90K
Relative Volume:
0.37
Marktkapitalisierung:
$7.53B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
21.11
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-5.30%
1M Leistung:
-19.69%
6M Leistung:
-17.04%
1J Leistung:
+4.49%
1-Tages-Spanne:
$63.22
$64.58
1-Wochen-Bereich:
$63.22
$68.40
52-Wochen-Spanne:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
63.78 | 7.50B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.36 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.68 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.39 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.56 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.18 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - simplywall.st
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme names David Ramsay as interim CFO - Investing.com South Africa
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Halozyme Therapeutics COO Sells $599,000 in Shares - National Today
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock - MarketBeat
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery By Investing.com - Investing.com Canada
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery - Investing.com
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics - National Today
Neo Ivy Capital Management Cuts Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Victory Capital Management Trims Halozyme Therapeutics Stake - National Today
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment - marketscreener.com
Drug combo for relapsed or refractory myeloma cuts progression or death risk 83% - Stock Titan
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case - ChartMill
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
Snyder Capital Management L P Sells 663,853 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Shares Sold by Investment Firm - National Today
Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC - MarketBeat
Cresset Asset Management LLC Reduces Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,393,800.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback - Yahoo Finance
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns - Yahoo Finance
Segall Bryant & Hamill LLC Sells 94,261 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Fisher Asset Management Boosts Stake in Halozyme Therapeutics - National Today
Fisher Asset Management LLC Purchases 29,147 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Earnings History & Surprises | EPS & Revenue Results | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at TD Cowen Health Care Conference: Strategic Growth Insights - Investing.com
Halozyme Therapeutics (HAM:RV7) Total Operating Expense : €318 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB - National Today
Halozyme Therapeutics (HAM:RV7) Investments And Advances : €0 Mil (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Stock Holdings Reduced by Rafferty Asset Management - National Today
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by Rafferty Asset Management LLC - MarketBeat
Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unlocking A 21.53% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Option Exercise |
33.51 |
1,546 |
51,806 |
15,912 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 09 '26 |
Sale |
67.80 |
20,000 |
1,356,072 |
14,366 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Sale |
67.64 |
8,857 |
599,087 |
7,055 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):